137 related articles for article (PubMed ID: 29472375)
1. B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
Jaitly V; Wang W
Blood; 2018 Feb; 131(8):941. PubMed ID: 29472375
[No Abstract] [Full Text] [Related]
2. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
3. IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house.
Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Minervini CF; Brunetti C; Impera L; Ricco A; Cellamare A; Specchia G; Albano F
Ann Hematol; 2014 Sep; 93(9):1605-7. PubMed ID: 24408161
[No Abstract] [Full Text] [Related]
4. Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.
Ware AD; Birkness J; Duffield AS; Gocke CD
Virchows Arch; 2018 Jul; 473(1):131-135. PubMed ID: 29611054
[No Abstract] [Full Text] [Related]
5. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
[TBL] [Abstract][Full Text] [Related]
6. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
7. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
8. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
9. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
10. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
11. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
[TBL] [Abstract][Full Text] [Related]
12. A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F.
Acharya A; Vaniawala S; Parekh H; Sheikh H; Patel H; Ali R; Khan A; Nagee A; Kunjadia P; Mukhopadhyaya PN
Int J Lab Hematol; 2014 Aug; 36(4):e30-3. PubMed ID: 24033912
[No Abstract] [Full Text] [Related]
13. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.
Swierczek S; Nausova J; Jelinek J; Liu E; Roda P; Kucerova J; Jarosova M; Urbankova H; Indrak K; Prchal JT; Divoky V
Am J Hematol; 2013 Feb; 88(2):157-8. PubMed ID: 23280542
[TBL] [Abstract][Full Text] [Related]
14. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2.
Hussein K; Brakensiek K; Ballmaier M; Bormann M; Göhring G; Buhr T; Bock O; Kreipe H
Eur J Haematol; 2006 Dec; 77(6):539-41. PubMed ID: 17105449
[No Abstract] [Full Text] [Related]
15. JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosis.
Thachil J; Hawkins S; Woodcock B
Br J Haematol; 2011 Mar; 152(6):675. PubMed ID: 21219299
[No Abstract] [Full Text] [Related]
16. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.
Benedik-Dolničar M; Homan M; Brecelj J
J Pediatr Hematol Oncol; 2012 Apr; 34(3):243-4. PubMed ID: 21552144
[No Abstract] [Full Text] [Related]
17. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Grandone E; Guardascione MA; Margaglione M
Blood; 2007 Oct; 110(7):2768-9. PubMed ID: 17881638
[No Abstract] [Full Text] [Related]
18. Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera.
Kajikawa N; Seki Y; Fujio T; Okoshi Y; Hori M; Saito H; Iijima T; Kojima H
Intern Med; 2018 Nov; 57(22):3293-3297. PubMed ID: 29984752
[TBL] [Abstract][Full Text] [Related]
19. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
20. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
